Medtronic Archives - Page 38 of 59 - Medical Design Sourcing

Former Medtronic and Zimmer-Biomet VP joins back pain startup as CEO

Jeff Cambra, CEO of SpinaFX [Photo courtesy of SpinaFX]Jeff Cambra is the new CEO of SpinaFX Medical, the back pain therapy startup said on October 1.

Cambra was previously a vice president at Zimmer Biomet (NYSE:ZBH), “leading product management for their $5 billion global reconstruction business,” SpinaFX said in a news release. He served in that role from November 2020 to June 2021, according to his LinkedIn page.

He ended a nearly 11-year career at Medtronic (NYSE:MDT) in 2020, ultimately serving as vice president and general manager of interventional therapies. SpinaFX said he “led a successful turnaround of their $400 million vertebral augmentation and oncology business through new technology innovation, strategic partnerships, acquisitions and expanding margins.”

Get the full story at our sister site Medical Design & Outsourcing.

Former Medtronic and Zimmer-Biomet VP joins back pain startup as CEO

Jeff Cambra, CEO of SpinaFX [Photo courtesy of SpinaFX]

Jeff Cambra is the new CEO of SpinaFX Medical, the back pain therapy startup said on Friday.

Cambra was previously a vice president at Zimmer Biomet (NYSE:ZBH), “leading product management for their $5 billion global reconstruction business,” SpinaFX said in a news release. He served in that role from November 2020 to June 2021, according to his LinkedIn page.

He ended a nearly 11-year career at Medtronic (NYSE:MDT) in 2020, ultimately serving as vice president and general manager of interventional therapies. SpinaFX said he “led a successful turnaround of their $400 million vertebral augmentation and oncology business through new technology innovation, strategic partnerships, acquisitions and expanding margins.”

“With my passion for the interventional space, I constantly assess and monitor multiple promising technologies, I recognized the br…

Medtronic adds three new devices to minimally invasive spinal business

Medtronic (NYSE:MDT) this week announced that it has launched three new devices for its minimally invasive spinal technologies ecosystem.

The Dublin-based company launched its Catalyft PL and PL40 for the Catalyft expandable interbody system. Medtronic designed it for anterior rim engagement with a beveled tip for ease of insertion, integration with StealthStation Navigation, simplified bone graft delivery and active expansion at a precise angle and lift for minimally invasive sagittal alignment.

The company also launched its Space-D access system that enables pedicle-screw-based distraction, retraction and compression. It is compatible with Medtronic’s other screw system CD Horizon Solera Voyager.

Medtronic added the Accelerate graft delivery system with Grafton DBF to its minimally invasive product line. It allows for more controlled and efficient delivery of graft material into the disc space or other locations. The company said that it enables …

Medtronic wins CE mark approval for radial artery access portfolio

Medtronic today said it has received CE mark approval for its radial artery access portfolio.

The radial artery access devices include the Rist 079 radial access guide catheter and the Rist radial access selective catheter.

Medtronic designed the Rist 079 guide catheter to access the neuro vasculature through the radial artery instead of through the transfemoral artery.

Get the full story on our sister site, Medical Tubing + Extrusion.

Medtronic CFO offers supply chain update as medical device industry concerns mount

Medtronic CFO Karen Parkhill [Photo courtesy of Medtronic]Medtronic (NYSE:MDT) was among the participants in a White House semiconductor summit last week to address the continuing global shortage of electronic chips, but CFO Karen Parkhill says the world’s largest medical device manufacturer is not in same dire straits as chip buyers in other industries.

Medtronic’s supply chain is “holding up OK, but we’re seeing pressures like everybody else,” Parkhill said Friday in an interview with Medical Design & Outsourcing.

Get the full story at our sister site, Medical Design & Outsourcing.

Medtronic CFO offers supply chain update as medical device industry concerns mount

Medtronic CFO Karen Parkhill [Photo courtesy of Medtronic]

Medtronic (NYSE:MDT) was among the participants in a White House semiconductor summit last week to address the continuing global shortage of electronic chips, but CFO Karen Parkhill says the world’s largest medical device manufacturer is not in same dire straits as chip buyers in other industries.

Medtronic’s supply chain is “holding up OK, but we’re seeing pressures like everybody else,” Parkhill said Friday in an interview with Medical Design & Outsourcing.

“Semi-conductors are an issue. Resins are an issue,” she said. “I think it helps that we’re a medical device manufacturer that’s producing life-saving technology … because when push comes to shove, I think we’re more important than new cars coming off the line, for example. We haven’t necessarily pulled that card, but I do think that that could help if…

Medtronic’s IP dispute against Axonics could resume in court after PTAB decisions

Medtronic (NYSE:MDT) and Axonics (NSDQ:AXNX) could see their patent dispute over neurostimulation technology resume in court.

Yesterday, the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office affirmed an additional three patents in a long-term dispute between the companies over intellectual property for Medtronic’s Interstim sacral neuromodulation (SNM) system, completing the review process initiated by Axonics to challenge the validity of the seven total patents in the case brought by Medtronic, according to a news release.

“Medtronic appreciates the Patent Trial and Appeal Board’s efforts in this matter,” Medtronic EVP & president of the neuroscience portfolio Brett Wall said in the release. “We are pleased with the outcome of the review process and look forward to our day in court to protect the proprietary technology that brings SNM therapy to patients around the world.”

Following the …

Medtronic enrolls first patient in trial of growth modulation system for treating scoliosis

Medtronic (NYSE:MDT) announced today that it enrolled the first patient in a study for its Braive growth modulation system.

Fridley, Minn.-based Medtronic also completed the first surgical procedure in the BRAIVE investigational device exemption (IDE) study evaluating the safety and effectiveness of the Braive growth modulation system for treating progressive adolescent idiopathic scoliosis.

The first patient was recruited by The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom, according to a news release.

Braive uses a braid secured to the spine with screws to slow growth on the curved side of the spine while allowing growth to continue on the other side. The IDE study will evaluate the system’s safety and efficacy in correcting the spine curve in patients with juvenile or adolescent idiopathic scoliosis in the U.S., Canada and UK.

“Launching the BRAIVE IDE study is our latest step in bringing life-changing technolo…

Medtronic’s Hugo team ‘waiting for the phone call’ for approval in Europe

Medtronic’s Hugo robot-assisted surgery system [Image courtesy of Medtronic]It sounds like European approval of Medtronic’s soft tissue robotically-assisted surgery system, Hugo, could come any day now.

“We’re sitting at the tip of our chair waiting for the phone call that the product will be approved,” Medtronic EVP and EMEA President Rob ten Hoedt said Friday.

Fridley, Minnesota-based Medtronic (NYSE:MDT) filed for European approval in March, starting a process that takes about six to nine months. Medtronic’s now “in shooting range,” ten Hoedt said.

Get the full story at our sister site, Medical Design & Outsourcing.

Medtronic’s Pipeline Flex problems expand

The FDA today issued a notice confirming a Class I recall of the Pipeline Flex embolization device from Medtronic (NYSE:MDT).

Several models of the Pipeline Flex embolization device and Pipeline Flex embolization device with Shield Technology were affected, with 8,825 devices recalled in the U.S., having been distributed between April 18, 2019, and Aug. 13, 2020.

According to an FDA release, Medtronic initiated the recall on July 13, 2021. There have been 59 reported device malfunctions, 10 serious injuries and two deaths related to the recall.

The company recalled the devices due to a risk of the delivery system’s wire and tubes fracturing and breaking off when the system is in use to place, retrieve or move the stent inside a patient. Fractured pieces could stay inside the patient’s brain bloodstream, while there is the possibility that attempts to retrieve the fractured pieces may worsen the patient’s condition. The fragments can als…

Medtronic, Johnson & Johnson warn of hospital worker burnout headwind for medical devices

[Photo by Eugene Chystiakov]Medical device manufacturers are worried that the COVID-19 pandemic’s latest wave will make for a tougher recovery in elective procedures after Delta variant cases subside.

Top officials from Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), NuVasive (NASDAQ: NUVA) and Zimmer Biomet Holdings (NYSE:ZBH) warned investors that the highly contagious COVID-19 mutation filling U.S. hospitals with mostly unvaccinated patients is leaving a lasting mark on the healthcare workers who will be needed to catch up on routine procedures.

Johnson & Johnson’s hardest-hit business in the pandemic is its Medical Devices line, which faces another slowdown from elective procedures again delayed due to the Delta wave. But a looming shortage of hospital system workers is “a little bit of a new dynamic” facing the business, J&J CFO Joseph Wolk said Wednesday at the Morgan Stanley Global Healthcare Conference.

Get the full story at our sist…

Medtronic, Johnson & Johnson warn of hospital worker burnout headwind for medical devices

[Photo by Eugene Chystiakov]

Medical device manufacturers are worried that the COVID-19 pandemic’s latest wave will make for a tougher recovery in elective procedures after Delta variant cases subside.

Top officials from Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), NuVasive (NASDAQ: NUVA) and Zimmer Biomet Holdings (NYSE:ZBH) warned investors that the highly contagious COVID-19 mutation filling U.S. hospitals with mostly unvaccinated patients is leaving a lasting mark on the healthcare workers who will be needed to catch up on routine procedures.

Johnson & Johnson’s hardest-hit business in the pandemic is its Medical Devices line, which faces another slowdown from elective procedures delayed again due to the Delta wave. But a looming shortage of hospital system workers is “a little bit of a new dynamic” facing the business, J&J CFO Joseph Wolk said Wednesday at the Morgan Stanley Globa…